Full Press Release Details
IDEAYA Biosciences Reports IDE397 Interim Phase 1 Clinical Data.
IDYA
IDEAYA Biosciences Reports IDE397 Interim Phase 1 Clinical Data
Key Takeaway: IDEAYA Biosciences Reports IDE397 Interim Phase 1 Clinical Data
Price reaction · baseline $12.17 (2022-03-14 close) · hit after-hours · clean, no other IDYA news in the window
day 0 close · peak
-2.3%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+47%
120-day peak, hindsight
Typical move
5.2%
average across 6 past catalysts
Cash runway
~42 mo
Minimal dilution risk
Lead asset
IDE892
Phase 1 · NSCLC Adenocarcinoma